Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on June 22, 2020. The report details compensatory arrangements approved by the Compensation Committee of the Board of Directors for the Company's executive officers, effective June 1, 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee approved significant increases in base salaries and new equity grants for three executive officers:
- Chief Executive Officer: Base salary increased from $200,000 to $315,000; granted 200,000 incentive stock options.
- President: Base salary increased from $260,000 to $315,000; granted 100,000 incentive stock options.
- Chief Financial Officer: Base salary increased from $230,000 to $315,000; granted 150,000 incentive stock options.
Additionally, executive bonuses ranging from $20,000 to $80,000 were approved. The stock options have an exercise price of $1.33 per share, a ten-year term, and vest 50% on the one-year anniversary of the grant date, with the remainder vesting in eight equal quarterly installments starting September 30, 2021.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies beyond the standard disclosure of the compensation changes.
Key Facts for Investor Verification
- Verify the total annualized cost of the salary increases ($330,000 total increase across three officers).
- Confirm the dilution impact of the 450,000 newly granted incentive stock options.
- Review the vesting schedule to understand the retention timeline for key executives.
- Check the Company's cash position to ensure it can support the increased fixed salary obligations and potential bonus payouts.